Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Top Cited Papers
Open Access
- 15 November 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (10) , 3271-3279
- https://doi.org/10.1182/blood-2006-03-009142
Abstract
We conducted a phase 1/2 study of the combination of 5-aza-2′-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) inKeywords
This publication has 34 references indexed in Scilit:
- Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndromeLeukemia, 2005
- Combination therapy with DNA methyltransferase inhibitors in hematologic malignanciesNature Clinical Practice Oncology, 2005
- Increase in platelet count in older, poor‐risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all‐trans retinoic acidCancer, 2005
- Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic AgentsCancer Investigation, 2005
- Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidBlood, 2004
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004
- Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal CancerMolecular and Cellular Biology, 2003
- Methylation profiling in acute myeloid leukemiaBlood, 2001
- Valproic acid for the treatment of pediatric malignant gliomaKlinische Padiatrie, 1999
- Valproic AcidDrugs, 1994